Short-term intravenous antimicrobial prophylaxis for elective rectal cancer surgery: results of a prospective randomized non-inferiority trial

Surgery Today
Keiichiro IshibashiKensuke Kumamoto

Abstract

To investigate the non-inferiority of postoperative single-dose intravenous antimicrobial prophylaxis to multiple-dose intravenous antimicrobial prophylaxis in terms of the incidence of surgical site infections (SSIs) in patients undergoing elective rectal cancer surgery by a prospective randomized study. Patients undergoing elective surgery for rectal cancer were randomized to receive a single intravenous injection of flomoxef (group 1) or five additional doses (group 2) of flomoxef after the surgery. All the patients had received preoperative oral antibiotic prophylaxis (kanamycin and erythromycin) after mechanical cleansing within 24 h prior to surgery, and had received intravenous flomoxef during surgery. A total of 279 patients (including 139 patients in group 1 and 140 in group 2) were enrolled in the study. The incidence of SSIs was 13.7% in group 1 and 13.6% in group 2 (difference [95% confidence interval]: -0.2% [-0.9 to 0.7%]). The incidence of SSIs was not significantly different in patients undergoing elective rectal surgery who were treated using a single dose of postoperative antibiotics compared to those treated using multiple-dose antibiotics when preoperative mechanical and chemical bowel preparations were empl...Continue Reading

References

Apr 29, 1999·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·A J MangramW R Jarvis
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C A M MarijnenUNKNOWN Cooperative Investigators of the Dutch Colorectal Cancer Group
Jul 20, 2002·Current Opinion in Infectious Diseases·Christina Vandenbroucke-Grauls, Constance Schultsz
Jan 22, 2003·ANZ Journal of Surgery·Christopher Derek SuttonWilliam Michael Thomas
Apr 15, 2004·Annals of Surgery·Robert L SmithEugene F Foley
Apr 28, 2005·Chemotherapy·Ronald Lee NicholsChristopher B Weldon
Sep 1, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Peter GoldstrawUNKNOWN Participating Institutions
Apr 10, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Valerie W RuschUNKNOWN Members of IASLC Staging Committee
Jun 10, 2011·Diseases of the Colon and Rectum·Greta L KrapohlArden M Morris
Oct 18, 2011·International Journal of Clinical Oncology·Toshiaki WatanabeUNKNOWN Japanese Society for Cancer of the Colon and Rectum

❮ Previous
Next ❯

Methods Mentioned

BETA
dissection
lavage

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.